ABBOTT LABORATORIES (ABT)

Quarterly Report Filed: 2026-04-29

The filing contains extensive segment-level detail across Abbott's pharmaceutical, nutritional, and diagnostic product categories, with geographic breakdowns (US, Non-US, Key Emerging Markets) indicating comprehensive operational tracking for Q1 2026.
The document structure shows detailed tracking of common stock, treasury stock, retained earnings, and accumulated other comprehensive income components, suggesting potential share repurchase activity and capital allocation decisions during the quarter.
Multiple operating segments tracked including Established Pharmaceutical Products, Nutritional Products (Pediatric and Adult), and Diagnostic Products (Core Laboratory, Rapid and Molecular), indicating a diversified revenue base across healthcare categories.
The filing references both 2026 Q1 and comparative 2025 Q1 periods with consistent data structure, enabling year-over-year performance analysis across all major business segments and geographies.

Insider Trading Filed: 2026-04-29

Executive Vice President Mary K. Moreland acquired 5,314 ABT shares at $94.41 on 04/28/2026 through a Profit Sharing Trust, indicating insider confidence in the company's valuation at this price level.
Moreland disposed of 104,291 shares, a significantly larger transaction than the acquisition, suggesting either portfolio rebalancing, tax-loss harvesting, or liquidity needs rather than a bullish signal.
Post-transaction beneficial ownership stands at 17,159 shares held indirectly through the Profit Sharing Trust, representing a net reduction in direct insider stakes despite the recent acquisition activity.

Current Report Filed: 2026-04-27

Abbott expanded its Board of Directors from 12 to 13 members with the addition of Kevin Conroy on April 24, 2026, indicating continued corporate governance evolution and potential strategic shifts in board composition.
Shareholders overwhelmingly approved the new 2026 Incentive Stock Program (95.82% approval) with 140 million shares authorized, replacing the 2017 Program and providing Abbott with significant equity compensation capacity for employee and executive retention.
Strong shareholder support across all proposals, including 90.35% approval for executive compensation and 99.33% approval for the 2026 Employee Stock Purchase Plan for Non-U.S. Employees, demonstrates investor confidence in Abbott's management and strategic direction.
The comprehensive share count pool combining new 2026 Program authorization with recycled shares from the 2017 Program provides Abbott with substantial flexibility for long-term incentive awards and equity-based compensation strategies over the next decade.

Insider Trading Filed: 2026-04-27

Philip P. Boudreau, EVP and CFO of Abbott Laboratories, acquired 8,909 shares on 04/23/2026 at $92.04 per share through a Profit Sharing Trust, indicating insider confidence in the company at current valuations.
The CFO also purchased 2,200 shares on the same date at $91.50 per share for his spouse, demonstrating a meaningful personal investment commitment alongside his executive position.
Total beneficially owned shares reached 71,172 directly, plus 9,276 indirectly through the trust, representing substantial personal stake in the company's performance and strategic direction.
The transaction occurred via Rule 10b5-1 trading plan arrangement, suggesting these purchases were pre-planned as part of a structured investment strategy rather than opportunistic trading.

Current Report Filed: 2026-04-17

Abbott Laboratories has reached a settlement in a consolidated shareholder derivative lawsuit regarding its infant formula business, indicating a potential resolution to the legal issues.
The preliminary approval of the settlement and the upcoming final settlement hearing suggest that the company is working to address the concerns raised by shareholders and move forward.
The settlement details and any changes in governance or oversight measures will be important for investors to monitor, as they could impact the company's future operations and risk profile.

Insider Trading Filed: 2026-03-25

The reporting person, Jacob A. Orville, a Senior Vice President at Abbott Laboratories, has acquired 13,255 common shares of the company. This suggests continued confidence and alignment of the executive team with long-term shareholder value.
The shares were acquired through a restricted stock award under the company's 2017 Incentive Stock Program, with a 2-year vesting period. This type of compensation structure incentivizes the executive to focus on the company's long-term performance.
The transaction does not involve any derivative securities, indicating a straightforward acquisition of the company's common stock by the reporting person.

Current Report Filed: 2026-02-20

Abbott Laboratories is reducing the size of its board of directors from 13 to 12 members, effective April 24, 2026.
This change in board structure could signal a shift in the company's strategic direction or governance approach.
Investors should monitor for any additional changes to Abbott's leadership or corporate governance that may impact the company's long-term performance.

Annual Report Filed: 2026-02-20

Abbott Laboratories reported strong financial performance in 2025, with revenue growth across its key business segments including Established Pharmaceutical Products and Nutritional Products.
The company's profitability improved, with an increase in operating margins driven by cost optimization initiatives and favorable product mix.
Abbott provided a positive outlook for 2026, projecting continued revenue and earnings growth based on new product launches and expansion in emerging markets.

Insider Trading Filed: 2026-02-06

The reporting person, Daniel J. Starks, a director at Abbott Laboratories (ABT), acquired a total of 10,000 common shares of the company on February 4, 2026 at weighted average prices of $109.14 and $108.33 per share.
The reporting person also holds an indirect beneficial ownership of 258 common shares of ABT through the Alynne Starks 2012 Irrevocable Trust, of which he is the sole trustee.
The insider buying activity indicates that the director is confident in the company's future prospects and aligns with the interests of shareholders.

Insider Trading Filed: 2026-01-26

The reporting person, Robert B. Ford, who is the Chairman and CEO of Abbott Laboratories, acquired 18,800 common shares of the company at an average price of $107.1259 per share.
The shares were acquired through direct ownership and the Ford Family Trust, which the reporting person co-manages. This suggests that the CEO has confidence in the company's future performance and is willing to invest personal funds.
The reported transaction represents a relatively small increase in the reporting person's beneficial ownership, which already stood at over 469,000 shares prior to the transaction.

Current Report Filed: 2026-01-22

Abbott Laboratories announced strong financial results for Q4 and full year 2025, exceeding market expectations.
The company utilized non-GAAP financial measures to highlight its underlying operational performance, excluding one-time or unpredictable factors.
Management believes the presentation of non-GAAP metrics provides useful information to investors and aids in internal performance monitoring.

Important Information